# A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity

> **NCT04222790** · PHASE2 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 159 (actual)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** monosialic gangliosides
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04222790
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-28
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222790, "A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04222790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*